Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metabolic Syndrome
- Sponsor
- Seoul National Hospital
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- metabolic syndrome
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.
Detailed Description
Schizophrenic patients taking any kind of antipsychotics for at least 1 year at the Seoul National Hospital will be participated in this study. we are planning to enroll approximately 1000 patients with schizophrenia. For each subject * abdominal circumference * body mass index * lipid profile : TG, HDL-chlo, total chol * systolic/diastolic blood pressure * fasting blood glucose will be measured. we will calculate the rates of patients who meet the criteria for the Metabolic syndrome. 1. Abdominal obesity : absolute criteria 2. 2 or more of followings 1. Triglyceride ≥ 150mg/dL or ongoing treatment 2. HDL-cholesterol \< 40mg/dL (men) HDL-cholesterol \< 50mg/dL (female) or ongoing treatment 3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment 4. FBS ≥ 100mg/dL or previous diagnosis of type II DM
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients taking a same antipsychotics at least more than one year
- •schizophrenia or schizoaffective disorder
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
metabolic syndrome
Time Frame: cross-sectional
Secondary Outcomes
- each factor of metabolic syndrome